

undertaken by the current Commission (DG GROW) and MS to monitor the situation and identify technical solutions.

- On Turkey, AV promised to come back to Abbott but suggested that it is for Turkey to adapt its legislation.

Brexit

- Abbott explained that one of their key region for operations is UK and Ireland (85% of liquid skim milk in Northern Ireland) and asked AV the impact that Brexit could have in a no-deal scenario and how they can secure their production (milk produced in NI, but treated in IE);
- AV explained that no guarantees can be given in case of no deal, and a lot will depend on reciprocal actions by the UK. However, the EU is working on contingency plans since the beginning of Brexit discussions to protect EU market.

HTA

- Abbott fully supports the HTA proposal for a regulation, asked to be updated on the current negotiations in Council and explained why they, together with MedTech, believe that medical devices should not be included in the scope of the HTA proposal;
- AV mentioned that progress is being made in Council but that there are still negative countries. AV explained that the mandatory uptake must be understood as an obligation to not duplicate requests to industries to submit the same data to undertake the same clinical analysis. AV stressed that the Finnish presidency will start discussions on the legal text of the most controversial articles (articles 7 and 8 of the Austrian proposal). Discussions on the scope are taking place in Council and specific characteristics of medical devices are acknowledged.

Nutrition

- Abbott is active in the fight against infant obesity and called for an EU regulatory framework. Also, Abbott express the need to revise EU regulation on chlorine;
- AV shared the concerns and invited Abbott to raise these issues with the forthcoming Commission.

Priorities of DG SANTE for the next months and forthcoming term

- AV invited Abbott to read the Mission letter to Commissioner-designate Kyriakides where the main priorities of DG SANTE are outlined (cancer, nutrition, pharmaceuticals, e-health, supply of affordable medicines etc).

END

